ABSTRACT
Objective To study the clinical effect of Huangkui capsule combined with valsartan in the treatment of diabetic nephropathy.Methods50 patients with diabetic nephropathy treated in our hospital from April 2014 to October 2016 were selected as the research object in this study.They were randomly divided into the control group and the experimental group (n=two), with each group having a total of 25 patients.The control group was treated with valsartan treatment, patients in the experimental group of Huangkui capsule combined with valsartan treatment, comparative analysis of the experimental group and the control group of patients the treatment effect and total cholesterol and urinary albumin excretion rate.ResultsBefore treatment, there was no significant difference between the experimental group and the control group in terms of triglyceride, total cholesterol and urinary albumin excretion rate, and there was no statistical significance.After treatment, the urinary protein excretion rate and cholesterol and triglyceride levels in the experimental group were significantly lower than those in the control group, with statistical difference (P<0.05).In the control group of 25 patients, the total effective number of cases in the case of 20 cases, the effective rate was 80.0%.In the control group of 25 patients, the total effective number of cases in the case of 24 cases, the effective rate was 96.0%.As a result, the treatment effect of the patients in the control group was significantly lower than that in the experimental group, with statistical difference (P<0.05).There were no serious complications in diabetic nephropathy patients in the experimental group and the control group.ConclusionHuangkui capsule combined with valsartan in the treatment of diabetic nephropathy can improve the treatment efficiency to a great extent, high safety, no significant adverse reactions, improve the quality of life of patients, the maximum extent to reduce the pain of patients, with further clinical promotion and application significance.
ABSTRACT
Objective To investigate clinical effect of esomeprazole, mosapride, magnesium plus aluminum in patients with reflux esophagitis. Methods 98 patients with reflux esophagitis who were treated in our hospital from October 2014 to October 2016 were selected and randomly divided into control group and observation group, with 49 cases in each group.In the control group, patients were treated with esomeprazole and mosapride.In the observation group, patients were given esomeprazole, mosapride and magnesium plus aluminum.The levels of serum gastrin, serum motilin and 24-hour pH in the esophagus were compared before and after treatment .Results After treatment,The levels of serum gastrin and serum motilin in the observation group were significantly higher than those in the control group, the difference was statistically significant (P<0.05), while the total time percentage of pH<4 at standing position, total time percentage of pH <4 at supine position, total reflux time percentage of pH <4, and the duration of continuous reflux≥five mins in the observation group were significantly lower than those in the control group, the difference was statistically significant (P<0.05). Conclusion Esomeprazole, mosapride and magnesium plus aluminum have significant clinical effect in patients with reflux esophagitis, and can effectively reduce 24-hour pH in the esophagus, decrease the number of reflux, increase serum gastrin and serum motilin levels.